JPWO2020128872A5

JPWO2020128872A5 -

Info

Publication number: JPWO2020128872A5
Application number: JP2021535505A
Authority: JP
Publication date: 2022-12-26

Claims

An accessory for an injection device having a needle cap, said accessory comprising:
a body portion comprising a recess adapted to receive said injection device;
A cover coupled to the body portion about at least one drive, the cover having an open position exposing the recess to receive the injection device and an open position at least partially closing the recess. a cover pivotable between a closed position holding the injection device to the body portion;
a cap remover comprising a grip adapted to hold the needle cap, the cap remover being movable with respect to the body portion;
The cover is
a proximal end adapted to be moved by a user to move the cover from the open position to the closed position;
at least one distal extension extending distally away from the at least one pivot;
a distal end provided at the end of the distal extension that engages the grip to move the grip when the cover is moved from the open position to the closed position; a distal end adapted to be moved toward the end of the accessory to at least partially remove the needle cap from the injection device.

The at least one pivot is
at least one opening in the body portion;
2. The accessory of claim 1 , comprising at least one protrusion within the cover, the at least one protrusion being rotatable within the opening.

3. An accessory according to claim 1 or claim 2, wherein the cover comprises a proximal extension extending proximally away from the at least one pivot.

4. The accessory of Claim 3 , wherein the distal extension is shorter than the proximal extension.

3. An accessory according to claim 1 or claim 2, wherein the distal end of the cover comprises a cover cam positioned within a decapper slot of the decapper.

6. The accessory of claim 5 , wherein rotation of the cover cam about a pivot axis acts the cover cam against the cap remover slot to translate the cap remover within the accessory. product.

The cover pivots from the open position to the closed position against the cover cam against the cap remover slot to move the cap remover toward the distal end of the accessory. 6. An accessory according to claim 5 , arranged to exert a

The gripper retains the needle cap while the cap remover slot is moved toward the distal end of the accessory to at least partially remove the needle cap from the injection device. 8. An accessory according to claim 7 , arranged.

The cover pivots from the closed position to the open position against the cover cam against the cap remover slot to move the cap remover toward the proximal end of the accessory. 6. An accessory according to claim 5 , arranged to exert a

3. An accessory as claimed in claim 1 or claim 2, wherein the cover is connected to the body portion by a pair of pivots.

11. The accessory of claim 10, wherein the cover comprises a pair of distal extensions each extending distally away from respective pivots of the pair of pivots.

3. A system for performing an injection, said system comprising said injection device having said needle cap and an accessory according to claim 1 or claim 2 .

The injection device
Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, hormone deficiency poisoning, pain, thrombosis, infections, diabetes, diabetic retinopathy, acute coronary syndrome, angina pectoris, myocardial infarction, atheromatous artery Antibodies (monoclonal antibodies, ustekinumab, golimumab, infliximab) for use in the treatment or prevention of sclerosis, cancer, macular degeneration, allergies, hay fever, inflammation, anemia, or myelodysplasia, or for the development of protective immunity , guselkumab, silkumab, adalimumab, rituximab, tocilizumab, centolizumab, centolizumab pegol, sarilumab, secukinumab, ixekizumab, or biosimilar versions thereof), etanercept, abatacept, anakinra, epoetin alfa, darbepoetin alfa, epoetin beta- Methoxypolyethylene glycol, peginesatide, hormones, antitoxins, pain control substances, thrombosis control substances, infection control or elimination substances, peptides, proteins, human insulin or human insulin analogues or derivatives, polysaccharides, DNA, RNA , enzymes, oligonucleotides, anti-allergic drugs, antihistamines, anti-inflammatory drugs, corticosteroids, disease-modifying antirheumatic drugs, erythropoietin, or vaccines . system.

13. A substance, by delivery of said substance to a human subject using the system of claim 12 , wherein said substance is rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, hormone deficiencies. poisoning, pain, thrombosis, infection, diabetes, diabetic retinopathy, acute coronary syndrome, angina pectoris, myocardial infarction, atherosclerosis, cancer, macular degeneration, allergy, hay fever, inflammation, anemia, or Antibodies (monoclonal antibodies, ustekinumab, golimumab, infliximab, guselkumab, silkumab, adalimumab, rituximab, tocilizumab, centolizumab, centolizumab pegol, sarilumab, secukinumab, ixekizumab, or biosimilar versions thereof), etanercept, abatacept, anakinra, epoetin alfa, darbepoetin alfa, epoetin beta-methoxy polyethylene glycol, peginesatide, hormones, antitoxins, pain control substances, thrombosis control Substances, substances for controlling or eliminating infections, peptides, proteins, human insulin or human insulin analogues or derivatives, polysaccharides, DNA, RNA, enzymes, oligonucleotides, anti-allergic drugs, antihistamines, anti-inflammatory drugs, adrenal glands A substance selected from the group consisting of corticosteroids, disease-modifying antirheumatic drugs, erythropoietins, or vaccines.

Antibodies (monoclonal antibodies, ustekinumab, golimumab, infliximab, guselkumab, silkumab, adalimumab, rituximab, tocilizumab, centolizumab, centolizumab pegol, sarilumab, secukinumab) to human subjects by using the system according to claim 12 , ixekizumab, or biosimilar versions thereof), etanercept, abatacept, anakinra, epoetin alfa, darbepoetin alfa, epoetin beta-methoxy polyethylene glycol, peginesatide, hormones, antitoxins, pain control agents, thrombosis control agents, infection disease control or elimination substances, peptides, proteins, human insulin or human insulin analogues or derivatives, polysaccharides, DNA, RNA, enzymes, oligonucleotides, anti-allergic drugs, antihistamines, anti-inflammatory drugs, corticosteroids, Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, hormone deficiency poisoning, pain, thrombosis, infection by delivery of a substance selected from the group consisting of disease-modifying antirheumatic drugs, erythropoietin, or vaccines diabetes, diabetic retinopathy, acute coronary syndrome, angina pectoris, myocardial infarction, atherosclerosis, cancer, macular degeneration, allergy, hay fever, inflammation, anemia, or myelodysplasia or an injection device for use in developing protective immunity.